Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEPLISAV versus Engerix-B in adults with chronic kidney disease
2009-015877-11Phase 3Completed
- Sponsor
- Dynavax Technologies
- Start
- Jan 2010
- Modality
- Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in hepatitis B (HBV) comparing HEPLISAV 3-dose regimen with Engerix-B standard 4-dose regimen (2 arms). Primary endpoint: Seroprotection rate at Week 28. Started Jan 2010; status: completed.
02
Drugs
Heplisav-BHepatitis B vaccine
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on 2009-015877-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015877-11.